Literature DB >> 8473520

Hereditary tyrosinemia type I. Self-induced correction of the fumarylacetoacetase defect.

E A Kvittingen1, H Rootwelt, P Brandtzaeg, A Bergan, R Berger.   

Abstract

Two Norwegian patients with chronic tyrosinemia type I showed > 50% residual fumarylacetoacetase activity in liver samples obtained during liver transplantation. The enzyme characteristics of both patients were comparable with those of a normal control. Immunohistochemistry on liver sections from these patients and from three other Norwegian tyrosinemia patients revealed a mosaicism of fumarylacetoacetase immunoreactivity corresponding completely or partly to some of the regenerating nodules. This appearance of enzyme protein is presumably induced by the disease process. The mechanism involved remains unclear and could be caused by a genetic alteration, regained translation of messenger RNA, or to enhanced stability of an abnormal enzyme.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8473520      PMCID: PMC288163          DOI: 10.1172/JCI116393

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  15 in total

1.  Tissue fractionation studies. 6. Intracellular distribution patterns of enzymes in rat-liver tissue.

Authors:  C DE DUVE; B C PRESSMAN; R GIANETTO; R WATTIAUX; F APPELMANS
Journal:  Biochem J       Date:  1955-08       Impact factor: 3.857

Review 2.  Mitotic recombination in mammalian cells in vivo.

Authors:  A A Morley
Journal:  Mutat Res       Date:  1991 Sep-Oct       Impact factor: 2.433

3.  Hereditary tyrosinemia type I: lack of correlation between clinical findings and amount of immunoreactive fumarylacetoacetase protein.

Authors:  E A Kvittingen; H Rootwelt; T van Dam; H van Faassen; R Berger
Journal:  Pediatr Res       Date:  1992-01       Impact factor: 3.756

4.  Somatic mosaicism for DNA repair capacity in fibroblasts derived from a group A xeroderma pigmentosum patient.

Authors:  H R Chang; K Ishizaki; M S Sasaki; J Toguchida; M Kato; Y Nakamura; S Kawamura; T Moriguchi; M Ikenaga
Journal:  J Invest Dermatol       Date:  1989-10       Impact factor: 8.551

5.  The occurrence of hepatoma in the chronic form of hereditary tyrosinemia.

Authors:  A G Weinberg; C E Mize; H G Worthen
Journal:  J Pediatr       Date:  1976-03       Impact factor: 4.406

6.  Detection of succinylacetone and the use of its measurement in mass screening for hereditary tyrosinemia.

Authors:  A Grenier; A Lescault; C Laberge; R Gagné; O Mamer
Journal:  Clin Chim Acta       Date:  1982-08-04       Impact factor: 3.786

7.  Growth inhibitory activity of succinylacetone: studies with Walker 256 carcinosarcoma, Novikoff hepatoma and L1210 leukemia.

Authors:  D P Tschudy; P S Ebert; R A Hess; B C Frykholm; A Atsmon
Journal:  Oncology       Date:  1983       Impact factor: 2.935

8.  Assay of fumarylacetoacetate fumarylhydrolase in human liver-deficient activity in a case of hereditary tyrosinemia.

Authors:  E A Kvittingen; E Jellum; O Stokke
Journal:  Clin Chim Acta       Date:  1981-09       Impact factor: 3.786

9.  Different molecular basis for fumarylacetoacetate hydrolase deficiency in the two clinical forms of hereditary tyrosinemia (type I).

Authors:  R M Tanguay; J P Valet; A Lescault; J L Duband; C Laberge; F Lettre; M Plante
Journal:  Am J Hum Genet       Date:  1990-08       Impact factor: 11.025

Review 10.  Tyrosinaemia type I--an update.

Authors:  E A Kvittingen
Journal:  J Inherit Metab Dis       Date:  1991       Impact factor: 4.982

View more
  23 in total

Review 1.  Principles of therapeutic liver repopulation.

Authors:  Markus Grompe
Journal:  J Inherit Metab Dis       Date:  2006 Apr-Jun       Impact factor: 4.982

2.  In vivo selection of transplanted hepatocytes by pharmacological inhibition of fumarylacetoacetate hydrolase in wild-type mice.

Authors:  Nicole K Paulk; Karsten Wursthorn; Annelise Haft; Carl Pelz; Gregory Clarke; Amy H Newell; Susan B Olson; Cary O Harding; Milton J Finegold; Raymond L Bateman; John F Witte; Ronald McClard; Markus Grompe
Journal:  Mol Ther       Date:  2012-08-07       Impact factor: 11.454

Review 3.  P450-Humanized and Human Liver Chimeric Mouse Models for Studying Xenobiotic Metabolism and Toxicity.

Authors:  Karl-Dimiter Bissig; Weiguo Han; Mercedes Barzi; Nataliia Kovalchuk; Liang Ding; Xiaoyu Fan; Francis P Pankowicz; Qing-Yu Zhang; Xinxin Ding
Journal:  Drug Metab Dispos       Date:  2018-08-09       Impact factor: 3.922

Review 4.  Liver repopulation for the treatment of metabolic diseases.

Authors:  M Grompe
Journal:  J Inherit Metab Dis       Date:  2001-04       Impact factor: 4.982

Review 5.  Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione).

Authors:  E Holme; S Lindstedt
Journal:  J Inherit Metab Dis       Date:  1998-08       Impact factor: 4.982

6.  Therapeutic trials in the murine model of hereditary tyrosinaemia type I: a progress report.

Authors:  M Grompe; K Overturf; M al-Dhalimy; M Finegold
Journal:  J Inherit Metab Dis       Date:  1998-08       Impact factor: 4.982

7.  Tyrosinaemia type I--de novo mutation in liver tissue suppressing an inborn splicing defect.

Authors:  Y T Bliksrud; E Brodtkorb; P A Andresen; I E T van den Berg; E A Kvittingen
Journal:  J Mol Med (Berl)       Date:  2005-03-10       Impact factor: 4.599

8.  Curative ex vivo liver-directed gene therapy in a pig model of hereditary tyrosinemia type 1.

Authors:  Raymond D Hickey; Shennen A Mao; Jaime Glorioso; Faysal Elgilani; Bruce Amiot; Harvey Chen; Piero Rinaldo; Ronald Marler; Huailei Jiang; Timothy R DeGrado; Lukkana Suksanpaisan; Michael K O'Connor; Brittany L Freeman; Samar H Ibrahim; Kah Whye Peng; Cary O Harding; Chak-Sum Ho; Markus Grompe; Yasuhiro Ikeda; Joseph B Lillegard; Stephen J Russell; Scott L Nyberg
Journal:  Sci Transl Med       Date:  2016-07-27       Impact factor: 17.956

Review 9.  In vivo reversion to normal of inherited mutations in humans.

Authors:  R Hirschhorn
Journal:  J Med Genet       Date:  2003-10       Impact factor: 6.318

10.  A novel mutation causing mild, atypical fumarylacetoacetase deficiency (Tyrosinemia type I): a case report.

Authors:  David Cassiman; Renate Zeevaert; Elisabeth Holme; Eli-Anne Kvittingen; Jaak Jaeken
Journal:  Orphanet J Rare Dis       Date:  2009-12-15       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.